Across TCGA pan-cancer cohorts, LINC01906 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC01906’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC01906 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01906 is over-expressed in tumor.
BRCA are the cancer types where LINC01906 tumor–normal differential expression is most reproducible.